Abel Hall LLC
ARCT icon

Abel Hall LLC’s Arcturus Therapeutics ARCT Stock Holding History

Abel Hall LLC’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-16,142
Closed -$108K – 907
2026
Q2 		$108K Buy
+16,142
New +$127K 0.02% 825

Other funds holding ARCT

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
MGO One Seven
MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return
Apollon Wealth Management
Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return
Diversify Advisory Services
Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return
Diversify Wealth Management
Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Abel Hall LLC's ARCT Position: Q3 2026 in Review

Abel Hall LLC sold out of Arcturus Therapeutics (ARCT) in Q3 2026, closing a stake of 16,142 shares — an estimated $108K sold.

Abel Hall LLC first reported a position in ARCT in Q2 2026 and held it in 1 quarter. The position peaked at $108K in Q2 2026. 34 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Abel Hall LLC reported no remaining Arcturus Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Abel Hall LLC sold 16,142 Arcturus Therapeutics shares in Q3 2026, an estimated $108K.
  • Abel Hall LLC first reported a position in Arcturus Therapeutics in Q2 2026 and held it in 1 quarter.
  • Abel Hall LLC's Arcturus Therapeutics position peaked at $108K in Q2 2026.
  • 34 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.